Site icon OncologyTube

Efficacy & Tolerance Of TAK-788: Patients Had Diarrhea, Nausea, Mild Rash, & Chemical Pancreatitis, Appears To Be More Potent & Specific In Pre-Clinical Studies

Joel Neal MD Of Stanford University Medical Center Discusses Efficacy & Tolerance Of TAK-788: Patients Had Diarrhea, Nausea, Mild Rash, & Chemical Pancreatitis, Appears To Be More Potent & Specific In Pre-Clinical Studies.

Exit mobile version